Equasens Welcomes François-Pierre Marquier as New Director

Equasens Announces Leadership Change in Pharmagest Division
In a notable shift within the Equasens Group, François-Pierre Marquier has been appointed as the new Director of the Pharmagest Division, succeeding Damien Valicon. This change reflects the company's ongoing commitment to strengthening its leadership and operational capabilities in the evolving digital healthcare landscape.
Transition in Leadership
Damien Valicon has served as Deputy Chief Executive Officer and Director of the Pharmagest Division for 18 months, during which time he played a significant role in steering the company's operations. His departure marks a pivotal moment for Equasens as it embraces new leadership. François-Pierre's appointment was officially approved by the Board of Directors, chaired by Thierry Chapusot, reflecting a collective vision for the company’s future.
About François-Pierre Marquier
Joining Equasens in May 2021 as the Regional Director for the Ile-de-France region, François-Pierre Marquier quickly rose through the ranks, taking charge of the Pharmacy France business in January 2023. His extensive experience and deep understanding of the healthcare sector position him well to lead the Pharmagest Division into its next chapter. As he transitions into this role, François-Pierre aims to unify and enhance the division’s operations across France and Europe.
Vision for the Future
Denis Supplisson, the CEO of the Equasens Group, highlighted François-Pierre's profound understanding of the healthcare industry's intricacies. Supplisson remarked, 'François-Pierre has a deep understanding of our business sectors, a precise grasp of our challenges and the sectoral expertise we need to accelerate our European development.' This sentiment captures the essence of Equasens' strategy to drive growth and innovation under new leadership.
Upcoming Financial Communications
Equasens is set to publish its financial reports, with significant dates lined up: Q2 2025 revenue announcement is expected on the last day of July, followed by the H1 2025 results in late September. These communications will provide stakeholders with insights into the company’s performance
Empowering Healthcare Professionals
Equasens Group, a leader in digital healthcare solutions for over 35 years, is committed to enhancing the workflow of healthcare professionals across Europe. With a workforce of over 1,400 employees, the company focuses on developing specialized applications that streamline operations in private practices and healthcare establishments. This dedication to transforming healthcare practices underscores Equasens’ mission to provide innovative digital solutions that cater to the unique challenges faced by professionals in the sector.
Equasens' Commitment to Transformation
Equasens remains dedicated to fostering technological advancements that promote better patient care. Its tagline, 'Technology for a More Human Experience,' emphasizes the importance of interoperability in healthcare, facilitating improved communication and collaboration among professionals. As the digital landscape evolves, Equasens is well-positioned to adapt and lead in these critical changes.
Company Information
As a publicly listed company on Euronext Paris (Compartment B - FR 0012882389 – $EQS), Equasens balances its growth strategy between organic developments and strategic acquisitions. This approach aims to leverage opportunities across Europe, aligning with the company’s vision for sustainable expansion in digital healthcare.
CONTACTS
Analyst and Investor Relations:
Frédérique Schmidt, Chief Administrative and Financial Officer
Tel: +33 (0)3 83 15 90 67 - frederique.schmidt@equasens.com
Financial Communications Agency:
FIN’EXTENSO - Isabelle Aprile
Tel.: +33 (0)6 17 38 61 78 – i.aprile@finextenso.fr
Frequently Asked Questions
Who is François-Pierre Marquier?
François-Pierre Marquier is the newly appointed Director of the Pharmagest Division at Equasens, having previously served as Regional Director for the Ile-de-France region.
What changes occurred in the Pharmagest Division?
With the departure of Damien Valicon, François-Pierre Marquier has taken over as Director, signaling a renewed focus on operational effectiveness and growth.
What is Equasens Group's primary focus?
Equasens Group specializes in digital healthcare solutions, aiming to enhance the daily operations of healthcare professionals and improve patient care through innovative technologies.
When will Equasens share its financial results?
The company has scheduled its Q2 2025 revenue announcement for July 31, 2025, and the H1 2025 results for September 26, 2025.
How does Equasens support healthcare professionals?
Equasens provides comprehensive solutions that include digital tools, electronic equipment, and training tailored to the specific needs of healthcare providers.
About The Author
Contact Logan Wright privately here. Or send an email with ATTN: Logan Wright as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.